Nuwiq (Simoctocog Alfa)

Simoctocog alfa, the active ingredient in Nuwiq, is a recombinant factor VIII concentrate presented as a intravenous solution for IV use. It replaces deficient clotting factor VIII in patients with hemophilia A, helping to control and prevent bleeding episodes. GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nuwiq is a recombinant factor VIII product that acts within the coagulation cascade to manage bleeding disorders. - Hemophilia A (severe): Provides factor VIII replacement to prevent and control spontaneous bleeding. - Hemophilia A (moderate): Supports routine prophylaxis to reduce frequency of bleeds. - Hemophilia A (mild) with inhibitors: Used in immune tolerance induction protocols to help the immune system accept factor VIII. - Surgical prophylaxis in hemophilia A patients: Maintains adequate factor VIII levels during operative procedures. - On‑Demand  ‑         -   

These                   …      …  … …  …